


Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Dr. J. Leonard Lichtenfeld		
2. Your Title: Deputy Chief Medical Officer of the American Cancer Society, Inc.		
3. The Entity(ies) You are Representing: American Cancer Society, Inc. American Cancer Society Cancer Action Network, Inc.		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No X
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. I have not personally received any federal funds since January 1, 2015. Moreover, I have not been the principal investigator on any grants or contracts awarded to the American Cancer Society, Inc. since October 1, 2011. However, the American Cancer Society, Inc. received \$11,070,962 in Federal funds in 2015 and 2016.		
6. Please attach your curriculum vitae to your completed disclosure form. Attached in earlier email		

Signature:



Date: 2/2/17

CURRICULUM VITAE
of
J. Leonard Lichtenfeld, M.D., MACP

[REDACTED]

EDUCATION

B.A., Sociology with Honors, University of Pennsylvania
Philadelphia, PA

M.D., Hahnemann Medical College, Philadelphia, PA

PROFESSIONAL TRAINING

1971-72 Internship, Straight Medicine, Temple University Hospital
Philadelphia, PA

1972-75 Clinical Associate, Baltimore Cancer Research Center,
National Cancer Institute, National Institutes of Health
Baltimore, MD

1976-77 Assistant Resident, Department of Medicine
Johns Hopkins Hospital, Baltimore, MD

BRIEF CHRONOLOGY OF EMPLOYMENT

2001- American Cancer Society, Atlanta, GA

Deputy Chief Medical Officer	2002-
Cancer Control Science	2002-2014
Medical Editor	2001-2002

1998-01 Medical Director, Aspen Systems Corporation, Rockville, MD

(Medicare Integrity Program
Provider Safeguard Contracts for Provider Education and Evaluation/Management Draft
Guidelines Vignette Development)

1999-00 Executive Vice President, Expert Practice Inc., San Diego, CA

- 1999 Senior Physician Advisor, Public and Private Sector Advocacy, American Medical Association, Chicago, IL and Washington, DC
- 1996-98 Cornerstone Physicians Corporation, Irvine, CA
Senior Vice President, Physician Services
Chief Medical Officer
Vice President, Physician Development
- 1995-96 Drs. Brager, Gaber and Associates (Internal Medicine)
- 1977-95 J. Leonard Lichtenfeld MD PA (Primary Care Internal Medicine/Medical Oncology)
- 1977-85 Coordinator, Clinical Cancer Program
Sinai Hospital of Baltimore, Baltimore, MD
- 1975-76 Investigator, Baltimore Cancer Research Center, National Cancer Institute,
National Institutes of Health, Baltimore, MD

ACADEMIC APPOINTMENTS

- 1974-76 Fellow, Baltimore Cancer Research Center
University of Maryland Hospital, Baltimore, MD
- 1976-77 Fellow, Department of Medicine
The Johns Hopkins Hospital, Baltimore, MD
- 1977-86 Assistant Professor of Medicine
University of Maryland School of Medicine, Baltimore, MD
- 1977-02 Instructor, Department of Medicine
The Johns Hopkins University School of Medicine, Baltimore, MD

HOSPITAL AFFILIATIONS

- 2000-02 Emeritus Staff, Sinai Hospital of Baltimore
- 1998-00 Special Consultant, Sinai Hospital of Baltimore
Department of Medicine, Baltimore, MD
- 1977-98 Active Staff, Sinai Hospital of Baltimore
Department of OB/GYN, Baltimore, MD
- 1977-98 Active Staff, Sinai Hospital of Baltimore
Department of Medicine, Baltimore, MD
- 1977-02 Courtesy Staff, Department of Medicine
The Johns Hopkins Hospital, Baltimore, MD
- 1979-95 Courtesy Staff, Department of Medicine
Northwest Hospital Center, Randallstown, MD
- 1982-89 Courtesy Staff, Department of Medicine
Homewood Hospital Center, Baltimore, MD
- 1982-91 Consulting Staff, Department of Medicine
Levindale Hebrew Geriatric Center, Baltimore, MD

1995-96 Active Staff, Department of Medicine
St. Joseph Hospital, Towson, MD

1995-96 Active Staff, Department of Medicine
Mercy Hospital, Baltimore, MD

UNIFORMED SERVICE

1972-76 U.S. Public Health Service, BCRC, DCT, NCI

MEMBERSHIPS AND SOCIETIES

Alpha Omega Alpha
American College of Physicians
American Medical Association
American Society of Clinical Oncology
Johns Hopkins Medical Surgical Association
Johns Hopkins University Alumni Association
Medical Association of Georgia

BOARD CERTIFICATION

1972 National Board of Medical Examiners
1977 American Board of Internal Medicine
1977 Medical Oncology

LICENSURE

1975 State of Maryland (inactive)
2003 State of Georgia

EDITORIAL ACTIVITIES

1992-95; 96-06 Editorial Board, Physician's Practice Digest
1993-95; 96- Editorial Advisory Board, Internal Medicine News
1999-2003 Editorial Advisory Board, Medical Crossfire

HONORS & OTHER SPECIAL RECOGNITION

1966-67 Dean's List with Distinction, University of Pennsylvania, Philadelphia, PA

1971 Honors in Internal Medicine
Charles Block Memorial Prize in Medicine
Upjohn Research Award
Hahnemann Medical College, Philadelphia, PA

1983 Fellow, American College of Physicians

1987 Distinguished Internist of the Year (Maryland Society of Internal Medicine)

2005	Laureate Award, American College of Physicians (Georgia Chapter)
2007	Master, American College of Physicians
2011	Presidential Citation, American Academy of Dermatology Association
2013	
2011	Special Recognition Award, National Council on Patient Information and Education

OFFICES

American Society of Internal Medicine
Board of Trustees, 1990-97
Secretary-Treasurer, 1993-97
Internal Medicine Center to Advance Research and Education (IMCARE)
Board of Trustees, 1990-97
Secretary-Treasurer, 1993-97
American Society of Internal Medicine Political Action Committee
Board of Trustees, 1993-95
Maryland Society of Internal Medicine
Council 1983-94
Secretary-Treasurer, 1986-88
Vice-President, 1988-90
President, 1990-1992
Past President, 1992-94
Medical Staff, Sinai Hospital of Baltimore
Secretary-Treasurer, 1987
Medical Executive Committee, 1988
Levindale Hebrew Geriatric Center
Board of Directors, 1987-89
Medical and Chirurgical Faculty of Maryland
Board of Trustees, 1995-97
American College of Physicians, Georgia Chapter
Treasurer, 2007-2010

COMMITTEES

Sinai Hospital Medical Staff Committees
Cancer Committee, 1977-85
Budget and Finance Committee, Chairman, 1987
Budget and Finance Committee, Member, 1987-88
Utilization Review Committee, 1987
Quality Assurance Committee, 1987
Medical Records Committee, Chairman, 1990-91
Quality Assurance Committee, 1990-91
Department of Medicine Committee, 1993-96
Medical and Chirurgical Faculty of the State of Maryland
Preventive Medicine & Public Health Committee, 1978-81
Committee on Drugs, 1981-87

Legislative Committee, 1983-89; 1995-96
 Chairman, Insurance Subcommittee, 1986-87
 Co-Chairman, Legislative Committee, 1987-89
 Chairman, Legislative Committee, 1995-96
 Task Force Against Family Violence, 1993-96
 Focused Professional Education Committee (Ad Hoc), 1994

Chairman, Cancer Registry Advisory Committee, State of Maryland
 1982-91

American Society of Internal Medicine
 Delegate, Annual Meeting, 1986-90
 AIDS Task Force, 1987-88
 Health Insurance Benefits Committee, 1991-94
 Finance Committee (Chairman), 1993-97
 Personnel Committee (Chairman), 1993-97
 Investment Committee, 1993-97
 CPT/RBRVS Refinement Committee, 1994-98
 Computer Services Advisory Committee, 1997

Maryland Cancer Consortium for Data-Based Interventions
 Breast Cancer Detection Committee, 1990
 Cancer Data Subcommittee, 1990
 (State of Maryland Department of Health & Mental Hygiene)

American Medical Association
 RVS Update Committee, 1992-2016
 House of Delegates 1995-
 Alternate Delegate (ASIM), 1995-97
 Delegate (ASIM), 1997-98
 Delegate (ACP), 1998-

Agency for Health Care Policy Research, Department of Health
 and Human Services, Washington, DC,
 Quality Determinants of Mammography Panel, 1992-94

Health Care Access and Cost Commission, State of Maryland
 Payment System Advisory Committee (Alternate), 1994-96
 Pharmacy Benefit Advisory Committee, 1999-2001

American College of Physician
 Medical Services Committee, 1998-02; 2003-7
 Third Party Relations, Payment and Coding Subcommittee
 (Chairman 1998-02), 1998-2003, 2011-
 Members Insurance Subcommittee, 2007-2009

Georgia Chapter:
 Governor's Advisory Committee, 2004-
 Health and Public Policy Committee, 2004-
 Carrier Advisory Committee representative (Medicare), 2004-2010
 Treasurer, 2007-2010

Medical Mutual Liability Insurance Company, Hunt Valley, MD
 Claims Committee, 2000-01

National Council on Skin Cancer Prevention
 Steering Committee, 2003-

Medical Association of Georgia

Third Party Payors Committee, 2004-
 Medical Practice Committee (Chairman), 2006-7
 Delegate (Georgia Chapter, American College of Physicians), 2007-
 BCBS Provider Group Representative, 2014-

Aetna

National Physician Advisory Board, 2004-2016

National Council on Patient Information and Education

Board of Directors, 2004-2011
 Board Chair, 2008-2011

iHealth Alliance

Board of Directors, 2005-12

eHealth Initiative

Board of Directors, 2011-5
 Leadership Council, 2006-
 Blueprint Engaging Consumers Committee (co-chair), 2007
 Business and Clinical Motivators Workgroup, 2015-

Centers for Medicare and Medicaid Services

Medicare Evidence Development and Coverage Advisory Committee (MedCAC), 2007-10

American Society of Clinical Oncology

Health Services Committee, 2007-10
 AACR-ASCO-ACS-NCI Disparities Project 2013-

National Accreditation Program for Breast Centers

Board of Directors, 2009-

National Business Group on Health

National Advisory Committee on Employer Services for the Cancer
 Continuum of Care 2011-13

Blue Cross Blue Shield Association Best of Blue Awards Program

Reviewer 2008-2015

National Council on Skin Cancer Prevention

Steering Committee 2002-

Atlanta Business Leadership Initiative

Cancer Project Advisory Committee 2014-

Turning the Tide Against Cancer

Advisory Committee 2013-

Athena Breast Health Network: Wisdom (Mammography) Study

Advisory Committee 2014-

National Quality Forum
Cancer Project Standing Committee 2016-

Cahaba Government Benefit Administrators, LLC (Medicare)
Medicare Part B Advisory Group (Georgia Chapter ACP representative) 2016-

PUBLICATIONS

1. Lichtenfeld JL: Radiation therapy in the medical curriculum. J Med Educ 47:64-66, 1972.
2. Meadows A, Lichtenfeld JL, Koop CE: Wilm's tumor in three children of a woman with congenital hemihypertrophy. N Engl J Med 291:23, 1974.
3. Desner MR, Lichtenfeld JL, Dennison CL, Kalmbach KO, Mardiney MR, Jr: A new apparatus for BCG scarification. J Natl Cancer Inst 54:47-60, 1975.
4. Drake WP, Schumker M, Pendergrast JW, Davis A, Lichtenfeld JL, Mardiney MR, Jr: The importance of synthetic polynucleotide substrates in the elevation of abnormal nucleolytic activity associated with the sera of cancer patients. J Natl Cancer Inst 55:1055-1059, 1975.
5. Wiernik PH, Schimpff SC, Schiffer CA, Lichtenfeld JL, Aisner J, Fortner C: A randomized clinical comparison of daunorubicin alone with a combination of daunorubicin, cytosine arabinoside, thioguanine, and pyrimethamine for the treatment of acute non-lymphocytic leukemia. Cancer Treat Rep 60:41-53, 1976.
6. Schiffer CA, Lichtenfeld JL, Wiernik PH, Mardiney MR, Jr, Joseph JM: Antibody response in patients with acute non-lymphocytic leukemia. Cancer 37:2177-2182, 1976.
7. Lichtenfeld JL, Kirschner RH, Wiernik PH: Familial Sjögren's syndrome with associated primary salivary gland lymphoma. Am J Med 60:286-292, 1976.
8. Lichtenfeld JL, Wiernik PH: Levamisole in phase I trial. Cancer Treat Rep 60:963-964, 1976 (Letter to the Editor).
9. Wiernik PH, Lichtenfeld JL: Combined modality therapy for localized Hodgkin's disease. A seven year update of an early study. Oncology 32:208-213, 1975.
10. Lichtenfeld JL, Desner MR, Mardiney MR, Jr, Wiernik PH: The modulating effects of levamisole on human lymphocyte responsiveness in vitro. Cancer Treat Rep 60:571-574, 1975.
11. Lichtenfeld JL, Wiernik PH, Mardiney MR, Jr, Zarco RM: Abnormalities of complement and its components in patients with acute leukemia, Hodgkin's disease and sarcoma. Cancer Res 36:3678-3680, 1976.
12. Lichtenfeld JL, Wiernik PH, Shortridge DG: Phase I trial of levamisole in patients with non-resectable bronchogenic carcinoma, in Chirigos MA (ed.): Control of Neoplasia by Modulation of the Immune System. New York, Raven Press, 1977, 135-145.
13. Lichtenfeld JL: Current concepts in the management of malignant melanoma. Am J Med Sci 272:184-195, 1976.

14. Lichtenfeld JL: Malignant melanoma. Med Clin N Amer 61:1013-1025, 1977.
15. Lichtenfeld JL, Desner MR, Wiernik PH, Moore S, Mardiney MR, Jr: Amplification by levamisole of human lymphocyte responsiveness to immunological stimulation in vitro, in Chirigos MA (ed.): Modulation of Host Immune Resistance in the Prevention or Treatment of Induced Neoplasias. Fogarty International Center Proceedings #128. Washington DC, US Government Printing Office, 1977, 17-21.
16. Lichtenfeld JL: Tumor immunology, in Hematology and Oncology. MA Lichtman (ed.): New York, Grune & Stratton, Inc., 1980.
17. Lichtenfeld JL: Skin cancer, in Hematology and Oncology. MA Lichtman (ed.): New York, Grune & Stratton, Inc., 1980.
18. Lichtenfeld JL: Head and neck cancer, in Hematology and Oncology. MA Lichtman (ed.): New York, Grune & Stratton, Inc., 1980.
19. Van Echo DA, Chiuten DF, Gormley PE, Lichtenfeld JL: A Phase I clinical and pharmacological study of m-AMSA (NSC 249992) employing an intermittent every other week schedule. Cancer Res 39:3881-3884, 1979.
20. Van Echo DA, Chiuten DF, Whitacre M, Aisner J, Lichtenfeld JL, Wiernik PH: A Phase I trial of pentamethylmelamine (NSC 118742, PMM) in patients with previously treated malignancies. Cancer Treat Rep 64:1335-1339, 1980.
21. Bohlman ME, Lichtenfeld JL, Goldman SM: Lymph node calcification secondary to chemotherapy for histiocytic lymphoma. Diagnostic Imaging, 50:259-262, 1981.
22. Lichtenfeld JL: State mandated Medicare assignment. Maryland Medical Journal 37:71-74, 1988.
23. Lichtenfeld JL: Book Review: Molecular Foundations of Oncology, Samuel Broder (ed), Maryland Medical Journal 41:657, 1992.
24. Bassett LW, Hendrick RE, Bassford TL et al. Clinical Practice Guideline: Quality Determinants of Mammography. AHCPR Publication No. 95-0632. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, October 1994.
25. Bassett LW, Hendrick RE, Bassford TL et al. High Quality Mammography: Information for Referring Providers. Quick Reference Guide for Clinicians No. 13. AHCPR Publication No. 95-0633. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, October 1994.
26. Lichtenfeld JL: The RBRVS: Fixing the Flaws. The Internist 36:13-16, 1995.
27. Lichtenfeld JL: Comparing Chickens and Patients Like Comparing Apples and Oranges – It's Not the Same Thing at All; Physician's Practice Digest 9(1):39, 1999.
28. Herdman R and Lichtenfeld L: Fulfilling the Potential of Cancer Prevention and Early Detection: An American Cancer Society/Institute of Medicine Symposium; The National Academies Press, Washington, DC (2004)
29. American College of Physicians: Kirschner N, Pauker SG, Stubbs JW, Newman MM, Basch P, Ejnes YD, Engel JZ, Fihn SD, Gunn SH, Hersh WR, Lahey MD, Lichtenfeld JL, Mazur EM, Sha MC: Information On Cost-Effectiveness: An Essential Product Of A National Comparative Effectiveness Program. Ann Intern Med. 2008 148(12): 956-61
30. Lichtenfeld JL. Cancer Care and Survivorship Planning: Promises and Challenges. J Oncol Pract 2009 5: 116-118

31. Lichtenfeld JL: Can the Beast be Tamed? The Woeful Tale of Accurate Health Information on the Internet. *Ann Surg Oncol* 19:701-702, 2012
32. Cokkinides V, Kirland D, Andrews K, Sullivan K, Lichtenfeld JL: A Profile Of Skin Cancer Prevention Media Coverage In 2009. *J Am Acad Dermatol.* 2012: 67(4); 570-5
33. Abernethy A, Abrahams E, Barker A, Buetow K, Burkholder R, Dalton WS, Foti M, Frueh F, Gaynor RB, Kean M, Khan Z, Lessor T, Lichtenfeld JL, Mendelsohn J, van't Veer L: Turning The Tide Against Cancer Through Sustained Medical Innovation: The Pathway To Progress. *Clin Cancer Res.* 2014: 20(5): 1081-6

ABSTRACTS

1. Lichtenfeld JL, Desner MR, Mardiney MR, Jr, Wiernik PH: Amplification of immunologically induced lymphocyte 3H thymidine incorporation by levamisole. *Fed Proc* 33:790, 1974.
2. Schiffer CA, Lichtenfeld JL, Mardiney MR, Jr: Antibody production in patients with leukemia. *Proc Amer Soc Clin Oncol* 16:238, 1975.
3. Drake WP, Pendergrast WJ, Jr, Lichtenfeld JL, Schumker M, Mardiney MR, Jr: Elevated nuclease activity is correlated with the presence of malignancy: the use of synthetic polynucleotide substrates. *Proc Amer Assoc Cancer Res* 16:132, 1975.
4. Lichtenfeld JL, Wiernik PH, Mardiney MR, Jr: Abnormalities of complement and its components in patients with acute leukemia, Hodgkin's disease and sarcoma. *Proc Am Soc Hematol* 18:173, 1975.
5. Lichtenfeld JL, Wiernik PH: Phase I trial of levamisole in non-resectable bronchogenic carcinoma. *Proc Amer Assoc Cancer Res* 17:65, 1976.
6. Chang P, Wiernik PH, Lichtenfeld JL, Schiffer CA: Levamisole (L), cytosine arabinoside (Ara-C), and daunorubicin (DNR) induction therapy of adult acute non-lymphocytic leukemia (ANLL). *Proc Amer Soc Clin Oncol* 19:370, 1978.
7. Smith FP, MacDonald JS, Wooley PV, Hoth DF, Smythe TA, Lichtenfeld JL, Levin B, Schein PS: Phase II evaluation of FAM, 5-fluorouracil (F), Adriamycin (A) and Mitomycin-C (M), in advanced pancreatic cancer (PC). *Proc Amer Soc Clin Oncol* 20:415, 1979.
8. Van Echo DA, Gormley P, Lichtenfeld JL, Scoltock M, Wiernik PH: A Phase I study of m-AMSA. *Proc Amer Soc Clin Oncol* 20:422, 1979.
9. Lichtenfeld JL, Van Echo DA, Aisner J, Wiernik PH: A Phase I trial of pentamethylmelamine (NSC 118742, PMM) in patients with previously treated malignancies. *Proc Amer Soc Clin Oncol* 21:3407, 1980.

Miscellaneous

Blogs and columns:

Dr. Len's Cancer Blog (www.cancer.org/drlen)
2005-

Cure Magazine: House Calls
2008-

Medpage Today: Through Len's Lens
 (<http://www.medpagetoday.com/HematologyOncology/LungCancer/48889>)
 2014-

Dr. Lichtenfeld has been a longstanding media resource for the American Cancer Society since 2001 in numerous print, radio and television media including all major networks and major newspapers among others both in the United States and internationally.

Dr. Lichtenfeld has testified at numerous state, congressional and federal regulatory committees and agencies on behalf of the American Cancer Society

Selected Meetings and Participations

World Innovation Summit for Health (Invited participant), Doha Qatar 11/29-30/16

Minneapolis Cancer Alliance Membership Meeting: "The Power of Partnerships in Cancer Control" (Speaker), Minneapolis MN 11/10/16

ACS Cancer Action Network Research and Innovation Breakfast: "Palliative Care" (Speaker), Minneapolis MN 11/10/16

Fortune Magazine Brainstorm Health 2016 (Invited participant), San Diego CA 11/1-2/16

MIT CanceRX meeting (Advisory committee member and invited participant), Boston MA 10/26-28/16

MIT Laboratory for Financial Engineering/Dana Farber Cancer Center/Tapestry Networks: "Workshop on New Financing Structures for Transformative Care" (Panelist/Participant), Boston, MA 10/14/16

Minnesota Vikings Football Breast Cancer Survivors' Luncheon (speaker), Minneapolis-St. Paul, MN 10/5/16

General Mills Global Health, Women's Health Awareness Month: "Taking Care of You and Yours" (Lecture), Minneapolis-St. Paul, MN, 10/5/16

Association of Community Cancer Centers: "Institute for the Future of Oncology" (Invited participant), Chicago IL 6/30/16

MD Anderson Cancer Center: "Cancer Moonshot Summit" (Speaker and panel member), Houston TX 6/29/16

8th Biennial Cancer Survivorship Research Conference: "The Changing Landscape of Access to Care and Health Insurance" (Panel moderator), Washington DC 6/17/16

AdvaMedDx Board of Directors meeting: "The Changing Face Of Cancer Care and the Role of Diagnostics" (Speaker), Washington DC 6/16/16

Forbes 400 Summit on Philanthropy: (Panelist/Participant), New York, NY 6/8/16

Atlantic Live (The Atlantic Magazine): "The Search For Answers: Fighting Rare Cancers Town Hall" (Panelist), ASCO event, Chicago IL 6/2/16

Health Datapalooza Conference: "To Sign Or Not To Sign" (Speaker and panel participant), Washington DC 5/10/16

ASCO 2016 Oncology Standards and Interoperability Summit (participant), Alexandria, VA 5/9/16

Flint Animal Cancer Center (Colorado State University) One Cure Event: “The Answer to Cancer May Be Walking Right Beside Us” (Keynote speaker), Denver, CO 4/16/16

48th Annual Southeastern Wisconsin Cancer Conference: Advances in Melanoma: “The New Frontier of Melanoma: Epidemiology and Prevention” (Speaker), Milwaukee, WI 4/9/16

2016 Cancer Conference for Community Health Workers: “Understanding Skin Cancer: Taking Care of the Skin You Are In” (Speaker), Milwaukee, WI 4/8/16

2016 Cancer Conference for Community Health Workers: “A Conversation About Cancer” (Speaker), Milwaukee, WI, 4/8/16

Molecular Med Tri-Con 2016: What Clinical Validity Means for Consumers and Clinicians in the New Era of Genomic Medicine (speaker/panelist), San Francisco, CA 3/8/16

Friends of Cancer Research: Immuno-Oncology Policy Advisory Group meeting, Washington DC, December 16, 2015

Indiana University Kelly School of Business Life Sciences Conferences Series Speaker: Personalized and Precision Medicine, Indianapolis, IN November 20, 2015

Agency for Health Research and Quality: Bringing Evidence to Practice: Participant, Rockville, MD 10/27/15

Office of Management and Budget: Discussion of sunlamp rule, Washington, DC 10/26/15

American Cancer Society Cancer Action Network: Personalized Medicine (Moderator) October 19, 2015, Ft. Lauderdale, FL

Commission on Cancer, American College of Surgeons: Genetic Screening (Speaker) September 28, 2015, Webinar

Mid Atlantic Colorectal Cancer Forum: Colon Cancer Screening 80x18 (Speaker), September 18, 2015, Washington, DC

World CDx Conference: Maximizing the Impact of Companion Diagnostics for Patient: “Are We Prepared for the Genomics Revolution?” (Speaker), September 10, 2015, Boston MA

Houston Corporate Wellness Forum: “Wellness In The Workplace: Through The Cancer Lens” (Speaker), September 1, 2015, Houston TX

HL7 Genomics Policy Group: “Precision Medicine Is Being Led By Cancer Genomics” (Speaker, July 20, 2015, Washington, DC

National Marrow Donor Program symposium: Aligning Quality and Value in Stem Cell Transplantation (panel participant), July 16, 2015, Minneapolis MN

Association of Community Cancer Centers: 3rd Institute for the Future of Oncology (Participant), June 25, 2015, Chicago IL

United Healthcare: “Taking Care of the Skin You're In: Tips for Staying Safe in the Sun” (Speaker), webinar, June 16, 2015

Institute of Medicine symposium: IOM National Cancer Policy Forum Workshop on Comparative Oncology (Speaker), June 8, 2015, Washington DC

Astra Zeneca/National Journal: Biomedical innovation and the House Committee on Energy and Commerce’s 21st Century Cures initiative (discussion participant), April 13, 2015, Washington, DC

American Urological Association, Southeastern Section Annual Meeting, Savannah GA, March 20-21, 2015:

“The Evolving Payment Environment: Will You Be In Or Will You Be Out?”
“One Year Later: The Impact of the Affordable Care Act?”

American College of Preventive Medicine: Care Among Individuals with Health Insurance: Strategies for Closing the Gap (Speaker); Atlanta GA, February 25, 2015

Massachusetts Institute of Technology: New Funding Models for Translational Medicine: The Boston/Cambridge BioFinance Consortium (Participant), Cambridge MA, February 23, 2015

Food and Drug Administration: Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests: Public Process for Classification and Prioritization (Panel participant); Rockville MD, February 20, 2015

World Innovation Summit for Health, WISH Foundation (Participant); Doha, Qatar, February 17, 2015

National Alliance For Hispanic Health: “A Journey In Transition: Cancer In The Latino Community” (Speaker); Webinar, February 9, 2015

Food and Drug Administration: Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs) (Panel Participant), Bethesda MD, January 9, 2015